Black Diamond Therapeutics (BDTX) Cash from Investing Activities (2019 - 2025)

Black Diamond Therapeutics' Cash from Investing Activities history spans 5 years, with the latest figure at -$2.9 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 110.4% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$44.9 million, down 364.65%, while the annual FY2025 figure was -$44.9 million, 364.65% down from the prior year.
  • Cash from Investing Activities reached -$2.9 million in Q4 2025 per BDTX's latest filing, down from $8.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $27.8 million in Q4 2024 to a low of -$59.2 million in Q2 2025.
  • Average Cash from Investing Activities over 3 years is -$2.7 million, with a median of $2.2 million recorded in 2024.
  • The largest YoY upside for Cash from Investing Activities was 291.7% in 2025 against a maximum downside of 8093.65% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at $3.5 million in 2021, then soared by 699.34% to $27.8 million in 2024, then plummeted by 110.4% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Cash from Investing Activities are -$2.9 million (Q4 2025), $8.6 million (Q3 2025), and -$59.2 million (Q2 2025).